- Disease (Renal cell carcinoma) [Japanese]
- Disease (Hepatocellular carcinoma) [Japanese]
- Summary report [Japanese]
- Summary report [English]
- Report (First-line renal cell carcinoma) [Japanese]
- Appendix of the report (First-line renal cell carcinoma) [Japanese]
- Report (Second-line renal cell carcinoma) [Japanese]
- Appendix of the report (Second-line renal cell carcinoma) [Japanese]
- Report (Hepatocellular carcinoma) [Japanese]
- Results of NDB analysis
[C2H2002] Cabozantinib (Cabometyx)
(Released on August 2nd, 2022)